Roche's investor science conference call from ECTRIMS 2015

We kindly invite investors and analysts to participate in a conference call on Monday, 12 October 2015 following the ECTRIMS annual international conference devoted to basic and clinical research in multiple sclerosis 7-10 October 2015 in Barcelona.

On the call, Roche will discuss new data from:

  • OPERA I and OPERA II, two Phase III studies designed to evaluate the efficacy and safety of ocrelizumab compared with interferon Β-1a (Rebif) in patients with relapsing multiple sclerosis

Conference call will start with presentations followed by a Q&A session.